Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

416P - Application of artificial intelligence: Machine learning for survival prediction in non-small cell lung cancer with brain metastases

Date

28 Mar 2025

Session

Poster Display session

Presenters

Julia Giner

Citation

Journal of Thoracic Oncology (2025) 20 (3): S241-S255. 10.1016/S1556-0864(25)00632-X

Authors

J. Giner1, P. Ribera Fernandez2, L. Vila Martinez2, A. Ribas Bravo3, O. Cano Cano2, P. Andreu Cobo2, M. Sierra Boada4, M. Fragio Gil4, S. Soriano2, A. Carrasco2

Author affiliations

  • 1 Hospital de Sabadell Corporacis Parc Tauli, Sabadell/ES
  • 2 Hospital Universitario Parc Taulí, Sabadell/ES
  • 3 Hospital Universitario Parc Taulí, 08208 - Sabadell/ES
  • 4 Parc Tauli Hospital Universitari, Sabadell/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 416P

Background

Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality, with brain metastases affecting 30–60% of patients and significantly worsening prognosis. Despite advances in systemic therapies, these patients are often excluded from clinical trials, limiting insights into effective treatments. This study aimed to develop a machine-learning model to predict survival in NSCLC patients with brain metastases and evaluate the impact of local treatments.

Methods

A retrospective cohort of 97 NSCLC patients with brain metastases treated at a single center was augmented with synthetic data (n=470) using the Synthetic Data Vault library. Predictive models, including Decision Trees, Random Forest (50 and 100 trees), and Deep Neural Networks (Deepnet), were trained using 38 clinical and molecular variables. Performance metrics included accuracy, sensitivity, F1-score, and AUC-ROC.

Results

The Random Forest model with 100 trees showed the best predictive performance (AUC-ROC: 0.7601, F1-score: 0.8188), out-performing Decision Trees and Deepnet. Among predictors, clinical variables such as ECOG performance status and molecular alterations, particularly EGFR mutations, contributed significantly to the models’ accuracy. Local treatments for brain metastases were associated with improved survival outcomes.

Conclusions

Machine learning models, particularly Random Forest, can effectively predict survival in NSCLC patients with brain metastases and support clinical decision-making. While results are promising, limitations such as small sample size and reliance on synthetic data highlight the need for further validation in larger, real-world cohorts.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.